news

recently, yiteng pharmaceutical is accelerating the ipo process, and all preparatory work is being carried out intensively, efficiently and orderly. with the advancement of edding's listing process, edding has not only further consolidated its leading position in the pharmaceutical industry, but also led the company to break through the waves with "quality first, innovation-driven, market demand-oriented" as its core engine!

yiteng goes on the market, quality comes first. its anti-infective drug base originated from eli lilly and company suzhou pharmaceuticals. after the transformation, it has focused on quality and built a quality management system that strictly follows international standards. it has been awarded gmp certification. the full dosage form of xikelao has become a benchmark for consistency evaluation of generic drugs, setting the benchmark for the consistency evaluation of generic drugs. yiteng's preparation for ipo has added important weight.

in terms of production technology, yiteng strives for excellence. adopt internationally leading module design to create a class d clean production area to ensure the purity and stability of the production environment. the combination of advanced pharmaceutical equipment and sophisticated electronic software and hardware systems, as well as a strictly trained workforce, ensure the accuracy of the production process. this extreme control over production details has won wide market recognition for yiteng's ipo.

at the same time, eden is well aware that innovation is the inexhaustible driving force for enterprise development. the r&d and production base of eden respiratory drugs located in suzhou biomedical industrial park is a vivid reflection of its innovative strength. this is the birthplace of eden’s star product, the new generation ics glucocorticoid irepine (fluticasone propionate aerosol inhalation suspension). relying on its unique six pharmacological advantages, irepine has demonstrated its success in the field of asthma treatment. it has excellent curative effect, especially in the use of low-dose hormones, and is especially friendly to adolescents and children. this innovative achievement not only ensures the acceleration of yiteng's ipo, but also injects new vitality into yiteng's listing.

in addition, market orientation drives yiteng to go public. taking wenxin as an example, starting from raw materials, through procurement, production, quality inspection, release and import, it spans 5 countries in the united states, europe and asia, and the entire journey exceeds 20,000 kilometers and involves five overseas professional factories. this top-level pharmaceutical supply chain ensures high-standard production and rapid response, helping high-quality products such as wenxin to sell well around the world. it not only consolidates the foundation for eton's listing, but also stimulates the market's enthusiastic expectations for eton's ipo.

with the acceleration of the ipo and eteng listing process, eteng is standing at a new historical starting point, preparing to welcome a broader stage. mr. ni xin, chairman and ceo of eteng pharmaceuticals, said: "those who implement the practice will remember its trees, and those who drink from its flow will remember its origins. eteng people will not change their original aspirations, stick to their true nature of serving the people, and will continue to work hard in future development dedicated to protecting people’s health and giving back society’s trust with high-quality pharmaceutical products and excellent medical services.”